[Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy 
for SCLC]

Small cell lung cancer (SCLC), characterized by high aggressiveness, early metastasis, and poor prognosis, has long been a major challenge in lung cancer treatment. In recent years, the advent of immune checkpoint inhibitors (ICIs) has significantly improved overall survival in patients with SCLC and has become a new standard of care; however, substantial room for further improvement in clinical outcomes remains. As an emerging T cell-targeted immunotherapy, delta-like ligand 3-T cell engager (DLL3-TCE) precisely directs T cells to attack tumor cells and have demonstrated breakthrough potential in the treatment of SCLC. Tarlatamab, a representative agent in this class, has been approved for clinical use, and multiple TCE agents are currently under clinical development. Although DLL3-TCE shows promising prospects in the clinical management of SCLC, as a novel therapeutic modality, many clinicians still lack an in-depth understanding of their mechanisms of action, appropriate patient populations, and clinical management. To standardize the clinical application of DLL3-TCE in China, the Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology convened a consensus panel to develop the Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy for SCLC based on evidence-based medicine and expert practical experience, with the aim of providing standardized guidance for the clinical use of DLL3-TCE agents.
.